Advocacy services for adults with health and social care needs: draft scope consultation
We are listening to your views on this NICE guideline. Comments close 22 January 2021.
Search results
364 results
-
-
Type 1 diabetes in adults: diagnosis and management (update): draft guidance consultation
We are listening to your views on this NICE guideline. Comments close 19 May 2021.
-
Looked-after children and young people: draft guidance consultation
We are listening to your views on this NICE guideline. Comments close 15 June 2021.
-
Metreleptin for treating lipodystrophy (HST14)
Evidence-based recommendations on metreleptin (Myalepta) for treating lipodystrophy in children and adults
-
Inotersen for treating hereditary transthyretin amyloidosis (HST9)
Evidence-based recommendations on inotersen (Tegsedi) for stage 1 and stage 2 polyneuropathy in adults with hereditary transthyretin amyloidosis
-
Migalastat for treating Fabry disease (HST4)
Evidence-based recommendations on migalastat (Galafold) for treating Fabry disease in people over 16
-
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)
Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 in children
-
Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations (HST11)
Evidence-based recommendations on voretigene neparvovec (Luxturna) for RPE65-mediated inherited retinal dystrophies in people with vision loss caused by inherit
-
Patisiran for treating hereditary transthyretin amyloidosis (HST10)
Evidence-based recommendations on patisiran (Onpattro) for treating hereditary transthyretin amyloidosis in adults with stage 1 and stage 2 polyneuropathy
-
Volanesorsen for treating familial chylomicronaemia syndrome (HST13)
Evidence-based recommendations on volanesorsen (Waylivra) for treating familial chylomicronaemia syndrome in adults
-
Elosulfase alfa for treating mucopolysaccharidosis type IVa (HST2)
Evidence-based recommendations on elosulfase alfa (Vimizim) for treating mucopolysaccharidosis type IVa in adults and children
-
Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (HST3)
Evidence-based recommendations on ataluren (Translarna) for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene in people aged
-
Eculizumab for treating atypical haemolytic uraemic syndrome (HST1)
Evidence-based recommendations on eculizumab (Soliris) for treating atypical haemolytic uraemic syndrome in adults and children
-
Strimvelis for treating adenosine deaminase deficiency–severe combined immunodeficiency (HST7)
Evidence-based recommendation on Strimvelis for adenosine deaminase deficiency–severe combined immunodeficiency
-
Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)
Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia (XLH) in children and young people
-
Asfotase alfa for treating paediatric-onset hypophosphatasia (HST6)
Evidence-based recommendations on asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia in adults and children
-
Eliglustat for treating type 1 Gaucher disease (HST5)
Evidence-based recommendations on eliglustat (Cerdelga) for treating type 1 Gaucher disease in adults
-
Generalised anxiety disorder and panic disorder in adults: management (CG113)
This guideline covers the care and treatment of people aged 18 and over with generalised anxiety disorder (chronic anxiety) or panic disorder (with or without agoraphobia or panic attacks). It aims to help people achieve complete relief of symptoms (remission), which is associated with better functioning and a lower likelihood of relapse.
-
Insect bites and stings: antimicrobial prescribing (NG182)
This guideline sets out an antimicrobial prescribing strategy for insect and spider bites and stings in adults, young people and children aged 72 hours and over, including those that occurred while travelling outside the UK. It aims to limit antibiotic use and reduce antibiotic resistance.
-
Metastatic spinal cord compression in adults: risk assessment, diagnosis and management (CG75)
This guideline covers detecting and managing metastatic spinal cord compression in adults with cancer that has spread to the spine. It aims to improve quality of life by promoting early detection and management, and reducing spinal cord damage and disability.
-
Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use (NG15)
This guideline covers the effective use of antimicrobials (including antibiotics) in children, young people and adults. It aims to change prescribing practice to help slow the emergence of antimicrobial resistance and ensure that antimicrobials remain an effective treatment for infection.
-
Inducing labour (CG70)
This guideline covers circumstances, methods and monitoring for inducing labour in pregnant women to avoid a pregnancy lasting longer than 42 weeks (known as a prolonged pregnancy) or if a woman’s waters break but labour does not start. It aims to improve the advice and care provided to women considering and undergoing induction of labour in hospital-based maternity units, midwifery led units and at home.
-
Gastro-oesophageal reflux disease in children and young people: diagnosis and management (NG1)
This guideline covers diagnosing and managing gastro-oesophageal reflux disease in children and young people (under 18s). It aims to raise awareness of symptoms that need investigating and treating, and to reassure parents and carers that regurgitation is common in infants under 1 year.
-
Alcohol-use disorders: prevention (PH24)
This guideline covers alcohol problems among people over 10. It aims to prevent and identify such problems as early as possible using a mix of policy and practice.
-
Neonatal parenteral nutrition (NG154)
This guideline covers parenteral nutrition (intravenous feeding) for babies born preterm, up to 28 days after their due birth date and babies born at term, up to 28 days after their birth. Parenteral nutrition is often needed by preterm babies, critically ill babies, and babies who need surgery.
-
Type 1 diabetes in adults: diagnosis and management (NG17)
This guideline covers care and treatment for adults (aged 18 and over) with type 1 diabetes.
-
Diabetes (type 1 and type 2) in children and young people: diagnosis and management (NG18)
This guideline covers the diagnosis and management of type 1 and type 2 diabetes in children and young people aged under 18. The guideline recommends how to support children and young people and their families and carers to maintain tight control of blood glucose to reduce the long-term risks associated with diabetes.
-
Diabetes in pregnancy: management from preconception to the postnatal period (NG3)
This guideline covers managing diabetes and its complications in women who are planning pregnancy or are already pregnant. It aims to improve the diagnosis of gestational diabetes and help women with diabetes to self-manage their blood glucose levels before and during pregnancy.
-
Behaviour change: digital and mobile health interventions (NG183)
This guideline covers interventions that use a digital or mobile platform to help people eat more healthily, become more active, stop smoking, reduce their alcohol intake or practise safer sex. The interventions include those delivered by text message, apps, wearable devices or the internet. The guideline only includes those that are delivered by the technology itself and not by healthcare professionals using technology to deliver interventions.
-
Autism spectrum disorder in under 19s: recognition, referral and diagnosis (CG128)
This guideline covers recognising and diagnosing autism spectrum disorder in children and young people from birth up to 19 years. It also covers referral. It aims to improve the experience of children, young people and those who care for them.
-
Colorectal cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomas (CG118)
This guideline covers using colonoscopy to check for signs of bowel cancer in people aged 18 and over with ulcerative colitis or Crohn’s disease (types of inflammatory bowel disease) or adenomas (also known as polyps). It aims to prevent cancer and prolong life by offering advice on identifying early bowel cancer in adults most at risk.
-
Coexisting severe mental illness (psychosis) and substance misuse: assessment and management in healthcare settings (CG120)
This guideline covers assessing and managing people aged 14 years and over with coexisting severe mental illness (psychosis) and substance misuse. It aims to help healthcare professionals guide people with psychosis with coexisting substance misuse to stabilise, reduce or stop their substance misuse, to improve treatment adherence and outcomes, and to enhance their lives.
-
Bedwetting in under 19s (CG111)
This guideline covers assessing and treating bedwetting in people aged under 19. It aims to reduce bedwetting and the distress this causes by explaining what to ask in an assessment, what advice to provide, and which treatments are effective.
-
Barrett's oesophagus: ablative therapy (CG106)
This guideline covers endoscopy treatments for people aged 18 and over with Barrett’s oesophagus and high-grade dysplasia or intramucosal cancer. It offers advice on which types of endoscopy treatments should be offered and how these should be used. It aims to improve choice of treatment for adults with Barrett’s oesophagus and improve quality of life and survival for those who cannot have surgery.
-
Behaviour change: general approaches (PH6)
This guideline covers a set of principles that can be used to help people change their behaviour. The aim is for practitioners to use these principles to encourage people to adopt a healthier lifestyle by, for example, stopping smoking, adopting a healthy diet and being more physically active.
-
Gallstone disease: diagnosis and management (CG188)
This guideline covers diagnosing and managing gallstone disease in adults. It aims to reduce variation in care by promoting the most effective treatments, and to improve the advice given to people with gallstone disease before and after treatment.
-
Improving outcomes for people with brain and other central nervous system tumours (CSG10)
This guideline covers how healthcare services for people with brain tumours and other central nervous system tumours should be organised. It aims to improve care by recommending which healthcare professionals should be involved and the types of hospital or cancer centre best suited to provide the care.
-
Improving supportive and palliative care for adults with cancer (CSG4)
This guideline covers best practice in developing and delivering cancer services for adults. It aims to ensure that people with cancer, and their families and carers, are well informed, cared for and supported from before formal diagnosis onward.
-
Improving outcomes in children and young people with cancer (CSG7)
This guideline covers how healthcare services for children and young people with cancer should be organised. It aims to improve care by recommending which healthcare professionals should be involved and the types of hospital or cancer centre best suited to provide the care.
-
Improving outcomes in head and neck cancers (CSG6)
This guideline covers how healthcare services for adults with head and neck cancers should be organised. It aims to improve care by recommending which healthcare professionals should be involved and the types of hospital or cancer centre best suited to provide the care.
-
Improving outcomes for people with sarcoma (CSG9)
This guideline covers how healthcare services for people with sarcoma should be organised. It aims to improve care by recommending which healthcare professionals should be involved and the types of hospital or cancer centre best suited to provide the care.
-
People's experience in adult social care services: improving the experience of care and support for people using adult social care services (NG86)
This guideline covers the care and support of adults receiving social care in their own homes, residential care and community settings. It aims to help people understand what care they can expect and to improve their experience by supporting them to make decisions about their care.
-
Faecal incontinence in adults: management (CG49)
This guideline covers assessing and managing faecal incontinence (any involuntary loss of faeces that is a social or hygienic problem) in people aged 18 and over. It aims to ensure that staff are aware that faecal incontinence is a sign or a symptom, not a diagnosis.
-
Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence (CG76)
This guideline covers medicines adherence in people aged 18 and over. It recommends how to encourage adherence to medicines by supporting and involving people in decisions about their prescribed medicines. It aims to ensure that a person’s decision to use a medicine is an informed choice.
-
Antisocial personality disorder: prevention and management (CG77)
This guideline covers principles for working with people with antisocial personality disorder, including dealing with crises (crisis resolution). It aims to help people with antisocial personality disorder manage feelings of anger, distress, anxiety and depression, and to reduce offending and antisocial behaviour.
-
Otitis media with effusion in under 12s: surgery (CG60)
This guideline covers surgical treatment of children younger than 12 years who have fluid buildup behind their eardrum (otitis media, also known as ‘glue ear’). It aims to improve hearing and quality of life in children with otitis media.
-
Acutely ill adults in hospital: recognising and responding to deterioration (CG50)
This guideline covers how patients in hospital should be monitored to identify those whose health may become worse suddenly and the care they should receive. It aims to reduce the risk of patients needing to stay longer in hospital, not recovering fully or dying. It doesn’t specifically cover the care of children, patients in critical care areas or those in the final stages of a terminal illness.
-
Borderline personality disorder: recognition and management (CG78)
This guideline covers recognising and managing borderline personality disorder. It aims to help people with borderline personality disorder to manage feelings of distress, anxiety, worthlessness and anger, and to maintain stable and close relationships with others.
-
Irritable bowel syndrome in adults: diagnosis and management (CG61)
This guideline covers diagnosing and managing irritable bowel syndrome (IBS) in people aged 18 and over. It details how to accurately diagnose IBS, and aims to improve the quality of life for adults with IBS by promoting effective management using dietary and lifestyle advice, pharmacological therapy and referral for psychological interventions.
-
Developing and updating local formularies (MPG1)
This guideline covers good practice for developing and updating local formularies in line with statutory requirements. It supports developing formularies that reflect local needs, reduce variation in prescribing, and allow rapid adoption of new medicines and treatments.